A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing ...

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating ...

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing ...

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the ...

An international clinical trial shows an innovative CAR-T cell immunotherapy is promising against aggressive T cell cancers and has manageable side effects.

Allogeneic CAR-T cell therapy is produced using CRISPR gene editing from cells donated by healthy individuals.

Cells change their metabolic profiles in response to underlying gene regulatory networks, but how can alterations in metabolism encode specific transcriptional instructions? Here, we show that forcing ...